This HTML5 document contains 79 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n20http://linked.opendata.cz/resource/drugbank/drug/DB01171/identifier/kegg-drug/
n23http://linked.opendata.cz/resource/drugbank/drug/DB01171/identifier/pubchem-substance/
n9http://linked.opendata.cz/resource/AHFS/
n22http://linked.opendata.cz/resource/mesh/concept/
n16http://linked.opendata.cz/resource/drugbank/drug/DB01171/identifier/drugbank/
n5http://linked.opendata.cz/resource/drugbank/dosage/
n24http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n15http://linked.opendata.cz/resource/drugbank/drug/DB01171/identifier/chemspider/
n11http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n7http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n21http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n13http://linked.opendata.cz/resource/drugbank/drug/DB01171/identifier/wikipedia/
n18http://linked.opendata.cz/resource/drugbank/drug/DB01171/identifier/pharmgkb/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n17http://linked.opendata.cz/resource/drugbank/drug/DB01171/identifier/bindingdb/
n19http://linked.opendata.cz/resource/drugbank/drug/DB01171/identifier/pubchem-compound/
n14http://linked.opendata.cz/resource/atc/
n8http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01171
rdf:type
n3:Drug
n3:description
A reversible monoamine oxidase inhibitor (MAOI) selective for isoform A (RIMA) used to treat major depressive disorder.
n3:dosage
n5:271B4DF3-363D-11E5-9242-09173F13E4C5 n5:271B4DF2-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:halfLife
1-2 hours (4 hours in cirrhotic patients); metabolites are renally excreted
n3:indication
For the treatment of depression.
owl:sameAs
n11:DB01171 n24:DB01171
dcterms:title
Moclobemide
adms:identifier
n13:Moclobemide n15:4087 n16:DB01171 n17:15613 n18:PA452615 n19:4235 n20:D02561 n23:46504667
n3:mechanismOfAction
The mechanism of action of moclobemide involves the selective, reversible inhibition of MAO-A. This inhibition leads to a decrease in the metabolism and destruction of monoamines in the neurotransmitters. This results in an increase in the monoamines, relieving depressive symptoms.
n3:synonym
Moclobemid 4-Chlor-N-(2-morpholinoethyl)benzamid Moclamine 4-Chloro-N-(2-(4-morpholinyl)ethyl)benzamide p-Chloro-N-(2-morpholinoethyl)benzamide Moclaime Aurorix Moclobemide Moclamide 4-Chloro-N-(2-morpholin-4-yl-ethyl)-benzamide Moclobemidum Moclobemida
n3:toxicity
LD50 (mouse) is 730mg/kg and LD50 (rat) is 1,300mg/kg. Signs of toxicity include hypertension, drowsiness, dizziness, confusion, tremors, headache, agitation, muscle rigidity and seizures.
n8:hasAHFSCode
n9:28-16-04-12
n3:foodInteraction
Food slows absorption a little. Avoid alcohol. Take after meals in order to minimize the risk of interaction with tyramine.
n3:proteinBinding
Approximately 50% (primarily to albumin)
n21:hasConcept
n22:M0106138
n3:IUPAC-Name
n4:271B4DF8-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B4DFE-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B4DFD-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4DFA-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B4DFB-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B4DFC-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B4DF6-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B4DF4-363D-11E5-9242-09173F13E4C5 n4:271B4E0E-363D-11E5-9242-09173F13E4C5 n4:271B4DF7-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B4DF5-363D-11E5-9242-09173F13E4C5
n8:hasATCCode
n14:N06AG02
n3:H-Bond-Acceptor-Count
n4:271B4E04-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B4E05-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B4DFF-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B4E00-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B4E02-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B4E01-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B4E03-363D-11E5-9242-09173F13E4C5
n3:absorption
Well absorbed from the gastrointestinal tract (> 95%). The presence of food reduces the rate but not the extent of absorption. Hepatic first pass metabolism reduces bioavailability to 45-70% following administration of a single dose, but increases to 80% with multiple dosing as a result of saturation of the first pass effect. Peak plasma concentrations are reached within 1 - 2 hours following oral administration.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
71320-77-9
n3:category
n3:containedIn
n7:271B4DE7-363D-11E5-9242-09173F13E4C5 n7:271B4DE8-363D-11E5-9242-09173F13E4C5 n7:271B4DF1-363D-11E5-9242-09173F13E4C5 n7:271B4DEF-363D-11E5-9242-09173F13E4C5 n7:271B4DF0-363D-11E5-9242-09173F13E4C5 n7:271B4DED-363D-11E5-9242-09173F13E4C5 n7:271B4DEE-363D-11E5-9242-09173F13E4C5 n7:271B4DEB-363D-11E5-9242-09173F13E4C5 n7:271B4DEC-363D-11E5-9242-09173F13E4C5 n7:271B4DE9-363D-11E5-9242-09173F13E4C5 n7:271B4DEA-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B4E0A-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B4E0C-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B4E0D-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B4E09-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B4E08-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4E0B-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B4DF9-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B4E06-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B4E07-363D-11E5-9242-09173F13E4C5